<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">Indian Journal of Ophthalmology</journal-id><journal-title-group><journal-title>Indian Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">0301-4738</issn><issn pub-type="epub">1998-3689</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18711263</article-id><article-id pub-id-type="pmc">2636143</article-id><article-id pub-id-type="publisher-id">IndianJOphthalmol_2008_56_5_357_42411</article-id><article-categories><subj-group subj-group-type="heading"><subject>Symposium</subject></subj-group></article-categories><title-group><article-title>Introduction and immunopathogenesis of acquired immune deficiency syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sudharshan</surname><given-names>S</given-names></name><degrees>DOMS</degrees></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Biswas</surname><given-names>Jyotirmay</given-names></name><degrees>MS</degrees></contrib></contrib-group><aff>Medical and Vision Research Foundations, Sankara Nethralaya,18, College Road, Chennai - 600 006, Tamil Nadu, India</aff><author-notes><corresp id="cor1">Correspondence to Dr. Jyotirmay Biswas, Medical and Vision ResearchFoundations, Sankara Nethralaya, 18, College Road, Chennai - 600 006,Tamil Nadu, India. Email: <email>drjb@snmail.org</email></corresp></author-notes><pub-date pub-type="ppub"><season>Sep-Oct</season><year>2008</year></pub-date><volume>56</volume><issue>5</issue><fpage>357</fpage><lpage>362</lpage><history><date date-type="received"><day>14</day><month>7</month><year>2007</year></date><date date-type="accepted"><day>18</day><month>3</month><year>2008</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Ophthalmology</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an  open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>India has a large number of patients with acquired immune deficiency syndrome (AIDS), the third largestpopulation of this group in the world. This disease was first described in patients with <italic>Pneumocystis</italic> pneumoniain 1981. Ocular lesions can occur at any stage of the disease but are more commonly seen at the late stages.Human immunodeficiency virus (HIV), the causative agent of AIDS is a retrovirus with RNA genome anda unique &#x02032;Reverse transcriptase enzyme&#x02032; and is of two types, HIV-1 and 2. Most human diseases are causedby HIV-1. The HIV-1 subtypes prevalent in India are A, B and C. They act predominantly by reducing theCD4+ cells and thus the patient becomes susceptible to opportunistic infections. High viral titers in theperipheral blood during primary infection lead to decrease in the number of CD4+ T lymphocytes. Onset ofHIV-1-specific cellular immune response with synthesis of HIV-1 specific antibodies leads to the decline ofplasma viral load and chronification of HIV-1 infection. However, the asymptomatic stage of infection maylead to persistent viral replication and a rapid turnover of plasma virions which is the clinical latency. Duringthis period, there is further decrease in the CD4+ counts which makes the patient&#x02032;s immune system incapableof controlling opportunistic pathogens and thus life-threatening AIDS-defining diseases emerge. Advent ofhighly active antiretroviral treatment (HAART) has revolutionized the management of AIDS though there isassociated increased development of immune recovery uveitis in a few of these patients.</p></abstract><kwd-group><kwd>Acquired immuno deficiency syndrome</kwd><kwd>CD4 cells</kwd><kwd>CD8 cells</kwd><kwd>CXCR4</kwd><kwd>highly active antiretroviral therapy</kwd><kwd>CCR5</kwd><kwd>human immune deficiency virus</kwd><kwd>immune recovery uveitis</kwd></kwd-group></article-meta></front><body><p>Since the report of an unusual occurrence of <italic>Pneumocystic carinii</italic>pneumonia in five cases on June 5, 1981 by Dr. Gotlieb and hiscolleagues - &#x02032;<italic>Pneumocystis</italic> pneumonia - Los Angeles&#x02032; Fasciclein the Bulletin of Morbidity and Mortality Weekly Report(MMWR),<xref ref-type="bibr" rid="ref1">1</xref> which was the first publication on this dreadedinfection, there have been numerous studies and case reportspertaining to this disease. Nobody imagined that this was thefirst glimpse of a global pandemic that would threaten the veryexistence of much of the globe. Twenty-five years later, the humanimmunodeficiency virus (HIV), the causative agent of acquiredimmune deficiency syndrome (AIDS) has reached virtually everycorner of the globe infecting more than 65 million till date. Thereare about 14,000 new HIV infections occurring globally each day,of which more than 95% are in developing countries. Eighty percent are due to heterosexual transmission and about 12,000 are inpersons aged 15 to 49 years (50% are women and about 50% are15 to 24-year-old). Of these, 25 millions have already died.<xref ref-type="bibr" rid="ref1">1</xref></p><p>India has a large number of patients with AIDS, thethird largest population of this group in the world. Humanimmunodeficiency virus was first identified in India in 1986in prostitutes in Chennai and later in intravenous (IV) drugabusers in Manipur. Currently, there are about 2.5 millionHIV-infected people in India.<xref ref-type="bibr" rid="ref2">2</xref> Ocular lesions associated withAIDS were first reported<xref ref-type="bibr" rid="ref3">3</xref> in India in 1995 and a series of100 consecutive patients<xref ref-type="bibr" rid="ref4">4</xref> in India was reported in 2000, bothfrom Sankara Nethralaya, Chennai. Since then, there havebeen several other reports from different parts of India ofocular lesions due to AIDS and we have recently reported themanifestations of ocular tuberculosis in AIDS.<xref ref-type="bibr" rid="ref5">5</xref></p><p>Progress has been probably far greater in this field than anyother area of medicine in recent years and the lessons learntfrom HIV research have broad applications to other fields ofmedicine. The lifetime cumulative risk of developing at leastone abnormal ocular lesion for a HIV-positive person rangesfrom 52-100% in various studies.<xref ref-type="bibr" rid="ref6">6</xref> Ocular lesions usually occurin the late phase of HIV infection but can also be an earlymanifestation of the disease.</p><p>The predominant site of action of the virus is on the viralreverse transcriptase enzyme and the cell of action is the CD4cell. We describe the immunology and pathogenesis of thevirus leading to disease.</p><sec sec-type=""><title>History</title><p>There have been many historical events in the evolution ofAIDS and its treatment.<list list-type="bullet"><list-item><p>1981: Epidemic first identified</p></list-item><list-item><p>1982: The term &#x02033;AIDS&#x02033; first coined</p></list-item><list-item><p>1983: Identification of the HIV virus</p></list-item><list-item><p>1985: First commercial test to detect HIV</p></list-item><list-item><p>1987: First antiretroviral drug released (Zidovudine-AZT)</p></list-item><list-item><p>1991: 2<sup>nd</sup> and 3<sup>rd</sup> anti-retrovirals (ARVs) released (Didanosine-DDI, Zalcitabine-DDC)</p></list-item><list-item><p>1995: First protease inhibitor released (Saquinavir)</p></list-item><list-item><p>1998: Three-drug therapy (Highly active antiretroviraltherapy-HAART) shown to delay sickness and death</p></list-item><list-item><p>1998: First non-nucleoside inhibitor released</p></list-item></list></p><p>The treatment of any patient with AIDS involves<list list-type="order"><list-item><p>Inhibiting the replication of the virus using antiretroviraldrugs</p></list-item><list-item><p>Treatment of opportunistic infections</p></list-item><list-item><p>Psychosocial support</p></list-item></list></p></sec><sec sec-type=""><title>Immunology</title><sec><title>Causative agent<xref ref-type="bibr" rid="ref7">7</xref></title><p>Human immunodeficiency virus is a human retrovirus withRNA genome and a unique &#x02032;Reverse transcriptase enzyme&#x02032;and is of two types, HIV-1 and HIV-2. Most human diseasesare caused by HIV-1. The HIV-1 subtypes prevalent in Indiaare A, B and C.</p><p>The virus (Virion) is 120 nm in diameter consisting of anouter envelope, a core shell of protein and a cone-shaped innercore containing RNA genome, &#x02032;Reverse transcriptase&#x02032; enzymeand core polypeptides [<xref ref-type="fig" rid="F1">Figure 1</xref>]; HIV-2, on the other hand,is known to have a milder and slower effect on the immunesystem. People who have AIDS-like symptoms but test negativefor HIV-1 should be tested for HIV-2.</p></sec><sec><title>CD4 cells<xref ref-type="bibr" rid="ref8">8</xref></title><p>T lymphocytes, or Thymus derived cells, compose 65-80% ofthe peripheral blood lymphocyte population, 30-50% of thesplenocyte population, and 70-85% of the lymph node cellpopulation. B lymphocytes compose 5-15% of peripheral bloodlymphocytes, 20-30% of splenocytes and 10-20% of lymphnode cells.</p><p>Both B cells and T cells can be further subdivided intospecialized subsets; B cells into those that synthesize fiveseparate classes of immunoglobulins and T cells into helper(CD4) and cytotoxic (CD8) cells. Helper (CD4) T cells &#x02033;help&#x02033;in the induction of an immune response, in the generation ofan antibody response and in the generation of other, morespecialized components of the immune response. Cytotoxic(CD8) T cells, as the name implies, are involved in cellkilling or cytotoxic reactions. Delayed type hypersensitivity(CD4) T cells are the classic participants in the chronicinflammatory responses characteristic of certain antigens suchas mycobacteria. Regulatory (CD8) T cells are responsiblefor modulating immune responses, thereby preventinguncontrolled, host-damaging inflammatory responses.</p><p>Mosmann and Coffman<xref ref-type="bibr" rid="ref9">9</xref> described two types of helper(CD4) T cells with differential cytokine production profiles.These CD4 and CD8 cells are the cells predominantly affectedin HIV infections. Normal CD4 counts are between 300 to 1000cells/cu mm.</p><table-wrap id="T0001" position="anchor"><caption><title>Correlation of CD4 cell count and HIV-associated oculardisease</title></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">CD4 count (cells/cu.mm)</td><td align="left" rowspan="1" colspan="1">Disease</td></tr><tr><td align="left" rowspan="1" colspan="1">1000</td><td align="left" rowspan="1" colspan="1">Normal</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c; 500</td><td align="left" rowspan="1" colspan="1">Kaposi sarcoma</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c; 500</td><td align="left" rowspan="1" colspan="1">Kaposi sarcoma</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Lymphoma</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Tuberculosis</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c; 250</td><td align="left" rowspan="1" colspan="1">Pneumocystosis</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Toxoplasmosis</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Retinal/conj microvasculopathy</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c; 100</td><td align="left" rowspan="1" colspan="1">Keratoconjunctivitis sicca</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Varicella zoster virus retinitis</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cytomegalovirus retinitis</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type=""><title>Course of HIV infection<xref ref-type="bibr" rid="ref10">10</xref></title><p>In approximately 50% of cases, primary HIV-1 infection remainsasymptomatic,<xref ref-type="bibr" rid="ref8">8</xref> whereas 50% of the patients develop flu-likesymptoms within the first four weeks after infection. Duringprimary infection, virus titers are extremely high in peripheralblood (up to 108 HIV-1 RNA copies/ml plasma) and the numberof CD4+ T lymphocytes decreases significantly. The onset ofHIV-1-specific cellular immune response and the subsequentsynthesis of HIV-1-specific antibodies lead to the decline ofplasma viral load to a patient-specific level and chronificationof HIV-1 infection. However, the asymptomatic stage of theinfection is accompanied by persistent viral replication inlymph nodes and a rapid turnover of plasma virions andCD4+ T lymphocytes, called the &#x02033;clinical latency&#x02033;. During thecourse of clinical latency, the number of CD4+ T lymphocytesdecreases continuously. As a consequence the patient&#x02032;s immunesystem is no more capable of controlling opportunisticpathogens and life-threatening AIDS-defining diseases emerge.The different stages of HIV-1 infection are commonly classifiedusing the center for disease control (CDC) system. This systemcombines clinical data and the number of CD4+ T lymphocytesfor HIV-1 infection classification.</p><sec><title>Pathogenesis</title><p>The main steps in the replicative<xref ref-type="bibr" rid="ref10">10</xref> cycle of HIV are:<list list-type="order"><list-item><p>The virus is attached to CD4 and the appropriate co-receptor. However, other molecules on these cells may alsoplay a role in the attachment of HIV, particularly chemokinereceptors such as CCR5 and CXCR4. This results in fusionof the viral envelope and the cellular membrane and therelease of viral nucleocapsid into the cytoplasm.</p></list-item><list-item><p>Following the uncoating, viral RNA is reverse transcribedby the reverse transcriptase (RT).</p></list-item><list-item><p>The resulting double-stranded proviral DNA migratesinto the cell nucleus and is integrated into the cellularRNA polymerase II. This host cell can be either latentlyor actively infected. If latently infected, no viral RNA isproduced and a productive infection may not develop. Ifactively infected, however, the cell may produce maturevirions by transcription of proviral DNA.</p></list-item><list-item><p>The proviral DNA is transcribed by the cellular RNApolymerase II. This transcription also generates messengerRNA (mRNA).</p></list-item><list-item><p>The mRNAs are translated by the cellular polysomes. In thecytoplasm, mRNA is translated into HIV-specific structuralproteins that are integrated with the viral core particles.</p></list-item><list-item><p>Viral proteins and genomic RNA are transported to thecellular membrane and are assembled there. Immaturevirions are released. Polypeptide precursors are processedby the viral protease to produce mature viral particles.These assembled virus particles then migrate to the plasmamembrane of the infected cell. The virus undergoes finalmaturation by a process of reverse endocytosis (budding)at the plasma membrane. Subsequent dissemination of thevirus occurs either through free infectious particles that arereleased by the budding process or more likely by cell tocell transfer.</p></list-item></list></p></sec><sec><title>Latency<xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref10">10</xref></title><p>HIV-1 infection of resting memory or naive CD4+ T cells,macrophages or mononuclear cells leads to a nonproductivelatent infection.<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref> The molecular mechanisms thatdetermine whether a virus is to interrupt or continue its lifecycle are stillunclear. Two forms of HIV-1 latency can be found in restingCD4+ T cells, a labile pre-integration form and a stable post-integration form. HIV-1 latency occurs even during highlyactive antiretroviral trerapy (HAART) that successfully reducesplasma viremia to undetectable levels. It has been shown thatnot only wild type but also resistant HIV-1 sequences persistin reservoirs. Although the number of latently infected cellsharboring replication-competent virus is very low, it showsminimal decay and appears to be sufficient to guaranteelifelong persistence of HIV in the majority of patients on currentantiretroviral regimes. To date, HIV-1 latency represents amajor barrier to virus eradication, immune response and genepolymorphisms in HIV-1 infection.<xref ref-type="bibr" rid="ref10">10</xref></p><p>The major cause for AIDS progression in HIV-1 infectedpatients is the decline of CD4+ T lymphocytes which arethe primary target for HIV and act as the crucial site for theinduction of specific humoral and cell-mediated immuneresponse. Thus, as a consequence of the slow but continuousdepletion of CD4+ T lymphocytes during the course ofinfection, immune defence is damaged and the infectedorganism becomes susceptible to opportunistic infections thatultimately lead to death.</p></sec><sec><title>Cellular immune response<xref ref-type="bibr" rid="ref9">9</xref></title><p>During primary infection and normally prior to seroconversion,activation of HIV-1-specific cytotoxic CD8+ T lymphocytes(CTL) occurs. Presumably, CTL response is more effectivein controlling viral replication rather than HIV-1-specificantibodies. Using quantitative techniques it could bedemonstrated that the number of HIV-1-specific CTL is inverselycorrelated with viral load.<xref ref-type="bibr" rid="ref13">13</xref> There are various mechanismsfor CTL-mediated virus inhibition. CTL recognition ofHIV-1-infected antigen-presenting cells occurs via the T cellreceptor (TCR). CTL TCR binds to viral peptides associatedwith MHC Class I molecules at the surface of infected cells andinduces the release of proteases and perforin leading to lysisof infected cells.<xref ref-type="bibr" rid="ref14">14</xref> The second mechanism is the interactionof Fas ligand (FasL) on the CTL surface with Fas moleculeson target cells resulting in apoptotic lysis of infected cells.<xref ref-type="bibr" rid="ref15">15</xref>Besides cell lysis, binding of CTL to HIV-1 infected cells inducesthe release of noncytotoxic antiviral acting compounds suchas interferon-alpha and the CC chemokines MIP-1alpha,MIP-1beta and RANTES.<xref ref-type="bibr" rid="ref16">16</xref> These chemokines are the naturalligands of the HIV-1 coreceptor CCR5 and were shown to becapable of inhibiting infection of CD4+ T lymphocytes byR5 HIV-1 strains. CD8+ T lymphocytes reportedly secretethe yet unidentified soluble CD8 antiviral factor (CAF). Thepivotal role of specific CTL for the control of viral replicationis supported by the observation that long-term nonprogressors(LTNP)<xref ref-type="bibr" rid="ref17">17</xref> frequently show extraordinary strong qualitativeand quantitative HIV-1-specific CTL response. It has beenreported that highly exposed but seronegative individuals haddetectable amounts of HIV-1-specific CTL. Irrespective of theobserved CTL response the primary cause for the preventionof seroconversion and chronification in these individuals isstill not proven.</p></sec><sec><title>Humoral immune response<xref ref-type="bibr" rid="ref10">10</xref></title><p>The contribution of specific humoral immune response appearsto play a minor role in controlling HIVndash;1 infection. Crucial forantibody-mediated reduction of HIV-1 viral particles is theamount of neutralizing antibodies rather than the amount oftotal specific antibodies. Binding of neutralizing antibodiesto viral particles mediates incorporation and destruction ofvirions by phagocytes. However, sera obtained from HIV-1infected patients are not capable of reducing significantly viralinfectivity <italic>in vitro</italic>.<xref ref-type="bibr" rid="ref18">18</xref> Additionally, no correlation between theamount of maternal neutralizing HIV-1-specific antibodiesin infected pregnant women and the rate of vertical HIV-1transmission could be observed.<xref ref-type="bibr" rid="ref19">19</xref> Moreover, antiviral activityof present neutralizing antibodies against HIV-1 glycoproteingp120 is frequently overcome by complete replacement ofneutralization-sensitive virus by immune escaping HIV-1variants, either by mutation-induced conformational gp120changes and/or by modified glycosylation patterns of gp120.Despite a multitude of antiretroviral mechanisms, the immunesystem of the majority of individuals does not have the abilityto prevent chronification of HIV-1 infection or to eradicateHIV-1 infected cells. The extraordinary high mutation rate ofHIV-1 leads to the implementation of viral strains, which escapefrom CTL recognition due to amino acid exchanges withinviral epitopes. As a consequence, viral replication and <italic>de novo</italic>infection of CD4+ T cells still occurs, leading to the breakdownof the immune system and to death.</p><p>In summary, the initial target cells of HIV - namely, CD4helper T cells and macrophages - show different cytopathiceffects. The T cells gradually become fewer as the virus replicates.Helper T cells are known to play a pivotal role in immunologicresponse, and a decrease in their number leads to immunedeficiency and subsequent secondary opportunistic infections.In contrast, the infected macrophages rarely undergo lysis ordecrease in number. These circulating infected cells harborthe HIV and may disseminate it throughout the body. Humanimmunodeficiency virus alters the immune-related functions ofthese infected monocytes/macrophages in the following ways:<list list-type="bullet"><list-item><p>Decreased migration response to chemoattractants</p></list-item><list-item><p>Defective intracellular killing of various microorganisms(such as <italic>toxoplasma</italic> <italic>gondii</italic> and <italic>candida</italic> species)</p></list-item><list-item><p>Reduced expression of Class II MHC molecules, whichimpairs the processing and presentation of antigen to helperT cells</p></list-item><list-item><p>Excessive production by the macrophages of tumor necrosisfactor-alpha which leads to dementia, wasting syndromeand unexplained fever.</p></list-item></list></p></sec></sec><sec sec-type=""><title>Highly active antiretroviral therapy<xref ref-type="bibr" rid="ref20">20</xref></title><sec><title>Antiretroviral drugs</title><p>The advent of potent antiretroviral therapy has had a profoundimpact on the ophthalmological manifestations of AIDSpatients. As these drugs lead to improved immune function,patients have fewer opportunistic infections.</p><p>With the discovery of the relationship between a highlevel of plasma viral RNA and an increased rate of diseaseprogression, therapeutic emphasis has been on reducingplasma viremia completely. Theoretically, all steps in the virallifecycle represent targets for antiretroviral therapy. However,till date the three major groups of drugs being used in theclinical practice are inhibitors of the reverse transcriptase(nucleoside/nucleotide, NRTI, and non-nucleoside, NNRTI)and the protease inhibitors (PI).</p><p>Introduction of HAART is a landmark event in the historyof AIDS therapy and involves the use of agents from at leasttwo distinct classes of antiretrovirals. The advent of HAART,including protease inhibitors in the treatment of AIDS, hasresulted in improvement of immune status with reductionin viral load in many patients with HIV/AIDS, as evidencedby laboratory and clinical reports.<xref ref-type="bibr" rid="ref21">21</xref> HAART has remarkablyreduced systemic and ocular morbidity among patients withAIDS. Many AIDS patients are living longer and enjoying ahigher quality of life. Immune reconstitution can take eightweeks or longer.</p><p>In the majority of HIV-1 infected individuals, HAARTresulted in increased CD4+ T cell counts and reduction ofplasma viremia to undetectable levels which can be maintainedfor years. However, long-term virological success of HAARTis limited by development of resistance, severe side-effects,pharmacokinetic interactions, or patients&#x02032; personal choice.Therefore, new antiretrovirals acting on alternative targets(to avoid cross-resistance with old compounds) and withimproved systemic tolerability profiles are required.</p><p>Currently, a wide variety of potential new antiretroviralsare under investigation, including integrase inhibitors, fusioninhibitors<xref ref-type="bibr" rid="ref10">10</xref> and maturase inhibitors.<list list-type="roman-lower"><list-item><p>Protease inhibitors (L-731, 988 and S-1360 compoundsinteracting with Tat/Tar (EM2487, tamacrazine, CGP 64222or CGA 137053)</p></list-item><list-item><p>Maturation inhibitors (PA-457, DSB)</p></list-item><list-item><p>NC inhibitors (inhibitors of the gp120-CD4 interaction(zintevir, FP-21399, BMS-378806, PRO542,BMS806,PRO140)</p></list-item><list-item><p>CXCR4 coreceptor blockers (AMD3100; AMD3465; ALX40-4C; T22, T134,T140),</p></list-item><list-item><p>CCR5 coreceptor antagonist (TAK-779, TAK-220, SCH-C,SCH-D, E913, AK-602 and NSC 651016) or</p></list-item><list-item><p>Fusion inhibitors (enfuvirtide)</p></list-item></list></p><p>The HAART-mediated improvement of immune functionin patients with AIDS may also alter the way the eye respondsto both opportunistic infections, especially cytomegalovirus(CMV) and to treatment, resulting in changes in the clinicalmanifestations of ocular lesions in AIDS. There have beennewer ocular diseases in those patients on HAART.<xref ref-type="bibr" rid="ref22">22</xref></p></sec><sec><title>HAART responders</title><p>A patient who shows an improvement in CD4 cell counts ofgreater than 60 cells/mm<sup>3</sup> and has maintained it for more thantwo months is by definition a person who has shown responseto HAART therapy. HAART therapy leads to decreased plasmalevels of HIV RNA and increased CD4 T-lymphocyte counts,with improved immune function in patients with HIV infection.This immune recovery has resulted in substantial decline inopportunistic infections and has allowed some patients withCMV retinitis to discontinue specific anti-CMV therapy withoutreactivation of eye disease.<xref ref-type="bibr" rid="ref23">23</xref></p><p>Clinical reports show a decrease in the incidence of CMVretinitis since the introduction of HAART. Tural <italic>et al</italic>.<xref ref-type="bibr" rid="ref24">24</xref> andMacDonald <italic> et al</italic>.,<xref ref-type="bibr" rid="ref25">25</xref> demonstrated that some patients whorespond to combined antiretroviral treatment with an increasein CD4 T-lymphocyte levels regain the ability to suppress CMVwithout specific anti-CMV therapy, thereby providing clinicalevidence of partial immune recovery in these patients.</p><p>Before the introduction of protease inhibitors, patients withCMV retinitis typically had CD4 T-lymphocyte counts less than50 cells/ml with minimal intraocular inflammation.<xref ref-type="bibr" rid="ref23">23</xref> Substantialintraocular inflammation has now been reported in somepatients with CMV retinitis who have had improved immunefunction with HAART. The ocular inflammation associated withclinical immune recovery in patients taking potent antiretroviralregimens is known as immune recovery uveitis (IRU).</p></sec><sec><title>Immune recovery uveitis</title><p>Immune recovery uveitis is a chronic intraocular inflammatorysyndrome, the clinical spectrum of which includesanterior segment inflammation, cataract, vitritis, papillitis,cystoid macular edema, epiretinal membrane, vitreoushemorrhage, retinal neovascularization, and proliferativevitreoretinopathy.<xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref27">27</xref> Since IRU in non-CMVretinitis eyes is not common, the ocular inflammation is postulated to be dueto the CMV infection itself, which causes breakdown in theblood ocular barrier.<xref ref-type="bibr" rid="ref28">28</xref> This may allow CMV antigens to leakout of the eye and give the antigen access to lymphoid organsand stimulate an antigen-specific immune response.</p><p>A recent report<xref ref-type="bibr" rid="ref29">29</xref> suggested that all patients presenting withthe clinical and ophthalmological characteristics of IRU showedthe presence of HLA B 8-18.</p></sec><sec><title>Vaccine</title><p>In the laboratory and the clinic, HIV continues to resist ourefforts to find a cure (eradication of the virus from an infectedindividual), or a vaccine.<xref ref-type="bibr" rid="ref1">1</xref> In 25 years, there has not been a singlewell-documented report of a person whose immune system hascompletely cleared the virus, with or without the help of theART. But HIV remains an entirely preventable disease in adults;behavior modification, condom use and other approaches haveslowed HIV incidence in many rich countries and a growingnumber of poor ones.</p></sec><sec><title>Immunological tests<xref ref-type="bibr" rid="ref30">30</xref></title><p>The important tests to detect HIV infection are<list list-type="order"><list-item><p>Antibody-based tests</p></list-item><list-item><p>HIV-2 P 24 antigen testing</p></list-item><list-item><p>Qualititative and quantitative HIV - 1 Plasma and peripheralblood monocyte culture (PBMC) test</p></list-item><list-item><p>RNA test</p></list-item><list-item><p>Noninvasive tests</p></list-item></list></p><p>The relative merits of different laboratory tests for HIV<xref ref-type="bibr" rid="ref30">30</xref><list list-type="order"><list-item><p>Antibody-based tests</p><list list-type="alpha-lower"><list-item><p>ELISA, HIV 1 viral lysates-based EIA, synthetic peptide,DNA-recombinant derived antigen</p><p>Sensitivity: 99.5%</p><p>Specificity: 98.5%</p><p>Duration of time required: About 90 min</p><p>Remarks: Minimum number of sera needed for testing -batch testing, equipment and expertise required, falsepositive results occur and is cost-effective if done inbatches of sera</p></list-item><list-item><p>Rapid HIV tests configured into flow-through cartridges -solid phase capture assays and Dot-immunoblot assays</p><p>Sensitivity: 96-99%</p><p>Specificity: 97-100%</p><p>Duration of time required: About 30-90 min</p><p>Remarks: Single serum samples can be tested, rapid; Nospecialized equipment needed and is cost-effective</p></list-item><list-item><p>Western blot antibodies to the following antigens HIV 1core proteins - p17, p24 and p55, polymerase - p31, p5and p66, Envelop - gp41, gp120 and gp160</p><p>Sensitivity: Variable</p><p>Specificity: 99-100%</p><p>Duration of time required: About 90 min</p><p>Remarks: Confirmatory test, Expertise required, donein batches, antibodies to envelope gp 41 and gp 120along with p23 core antigen - WB positive and this testis relatively expensive</p></list-item><list-item><p>Indirect immunofluorescence</p><p>Sensitivity: 96-99%</p><p>Specificity: 97-100%</p><p>Duration of time required: About 30-90 min</p><p>Remarks: Confirmatory test, equipment and expertiserequired and is expensive</p></list-item></list></list-item><list-item><p>HIV-1, p24 core protein - ELISA capture</p><p>Sensitivity: Variable</p><p>Specificity: 100%</p><p> Duration of time required: Several hours</p><p>Remarks: Viral load assay, increase indicates progression,limited role in diagnosis and is expensive</p></list-item><list-item><p>HIV-1 Plasma and PBMC Culture</p><p>Sensitivity: Low</p><p>Specificity: 100%</p><p>Duration of time required: Several hours </p><p>Remarks: Useful in obtaining viral isolates but is anexpensive test</p></list-item><list-item><p>Qualitative DNA PCR testing and Quantitative HIV - 1 RNAtesting. Proviral DNA and RNA in clinical samples</p><p>Sensitivity: 100%</p><p>Specificity: 100%</p><p>Duration of time required: Several hours</p><p>Remarks: Early &#x02033;window&#x02033; diagnosis, Quantitative,monitors viral load for therapeutic management,technically difficult and expensive test</p></list-item><list-item><p>Noninvasive methods. Oral Fluids, Urine and VaginalSecretions</p><p>Sensitivity: Low</p><p>Specificity: Low</p><p>Duration of time required: Up to 90 min</p><p>Remarks: Tests on easily available clinical samples -instead of blood, not yet standardized and is cost-effective</p></list-item></list></p><p>With further ongoing research, newer laboratory investigationsare being developed which would help in identifying theinfection earlier and more specifically.</p><p>Enhancement of our knowledge on the immunopathogenesisof HIV and its systemic manifestations has been very helpfulin the management of AIDS. The newer second and third lineHAART regimens are specifically based on our understandingof the basic mechanisms of immunology of HIV which hasbeen of great value in the management of drug-resistantstrains of HIV.</p></sec></sec></body><back><fn-group><fn><p>Source of Support: Nil</p></fn><fn><p>Conflict of Interest: None declared</p></fn></fn-group><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fanci</surname><given-names>AS</given-names></name></person-group><article-title>Twenty-five years of HIV-AIDS</article-title><source>Science</source><year>2006</year><volume>315</volume><fpage>409</fpage></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="gov"><article-title>HIV-AIDS epidemiological Surveillance and Estimation report for the year 2005</article-title><source>Indian National AIDS Control Organization (NACO)</source><year>2006</year><month>4</month></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>Badrinath</surname><given-names>SS</given-names></name></person-group><article-title>Ocular lesions in AIDS:A report of first two cases in India</article-title><source>Indian J Ophthalmol</source><year>1995</year><volume>43</volume><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">8818313</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Madhavan</surname><given-names>HN</given-names></name><name><surname>George</surname><given-names>AE</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Solomon</surname><given-names>S</given-names></name></person-group><article-title>Ocular lesions associated with HIV infection in India: A seriesof 100 consecutive patients evaluated at a referral center</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>129</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">10653406</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babu</surname><given-names>RB</given-names></name><name><surname>Sudharshan</surname><given-names>S</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><name><surname>Therese</surname><given-names>KL</given-names></name><name><surname>Biswas</surname><given-names>J</given-names></name></person-group><article-title>Ocular tuberculosis in acquired immunodeficiency syndrome</article-title><source>Am J Ophthalmol</source><year>2006</year><volume>142</volume><fpage>413</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16935585</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodge</surname><given-names>WG</given-names></name><name><surname>Seiff</surname><given-names>SR</given-names></name><name><surname>Margolis</surname><given-names>TP</given-names></name></person-group><article-title>Ocular opportunistic infectionincidences among patients who are HIV positive compared topatients who are HIV negative</article-title><source>Ophthalmology</source><year>1998</year><volume>105</volume><fpage>895</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">9593394</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Biswas</surname><given-names>J</given-names></name></person-group><article-title>Ocular lesions in AIDS in India</article-title><source>Practical guidelines for diagnosis and management</source><year>2001</year><publisher-loc>Chennai, India</publisher-loc><publisher-name>Gnanodaya Press</publisher-name></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><article-title>Basic and clinical science course. Intraocular inflammation and uveitis</article-title><source>Am Acad Ophthalmol</source><year>2005-2006</year><fpage>241</fpage><lpage>62</lpage></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mossman</surname><given-names>TR</given-names></name><name><surname>Coffman</surname><given-names>R</given-names></name></person-group><article-title>Two types of mouse helper T cellsclone: Implications from immune regulation</article-title><source>Immunol Today</source><year>1987</year><volume>8</volume><fpage>233</fpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierra</surname><given-names>S</given-names></name><name><surname>Kupfer</surname><given-names>B</given-names></name><name><surname>Kaiser</surname><given-names>R</given-names></name></person-group><article-title>Basics of the virology of HIV-1 andits replication - review</article-title><source>J Clin Virol</source><year>2005</year><volume>34</volume><fpage>233</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">16198625</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>TW</given-names></name><name><surname>Carruth</surname><given-names>L</given-names></name><name><surname>Finzi</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>DiGiuseppe</surname><given-names>JA</given-names></name><name><surname>Taylor</surname><given-names>H</given-names></name><etal/></person-group><article-title>Quantification of latent tissue reservoirs and total body viralload in HIV-1 infection</article-title><source>Nature</source><year>1997</year><volume>387</volume><fpage>183</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9144289</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chun</surname><given-names>TW</given-names></name><name><surname>Davey</surname><given-names>RT</given-names><suffix>Jr</suffix></name><name><surname>Ostrowski</surname><given-names>M</given-names></name><name><surname>Shawn</surname><given-names>JJ</given-names></name><name><surname>Engel</surname><given-names>D</given-names></name><name><surname>Mullins</surname><given-names>JI</given-names></name><etal/></person-group><article-title>Relationship between pre-existing viral reservoirs and there-emergence of plasma viremia after discontinuation of highlyactive anti-retroviral therapy</article-title><source>Nat Med</source><year>2000</year><volume>6</volume><fpage>757</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">10888923</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogg</surname><given-names>GS</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Bonhoeffer</surname><given-names>S</given-names></name><name><surname>Dunbar</surname><given-names>PR</given-names></name><name><surname>Nowak</surname><given-names>MA</given-names></name><name><surname>Monard</surname><given-names>S</given-names></name><etal/></person-group><article-title>Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA</article-title><source>Science</source><year>1998</year><volume>279</volume><fpage>2103</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">9516110</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMichael</surname><given-names>AJ</given-names></name><name><surname>Rowland-Jones</surname><given-names>SL</given-names></name></person-group><article-title>Cellular immune responses toHIV</article-title><source>Nature</source><year>2001</year><volume>410</volume><fpage>980</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11309628</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadida</surname><given-names>F</given-names></name><name><surname>Vieillard</surname><given-names>V</given-names></name><name><surname>Mollet</surname><given-names>L</given-names></name><name><surname>Clark-Lewis</surname><given-names>I</given-names></name><name><surname>Baggiolini</surname><given-names>M</given-names></name><name><surname>Debre</surname><given-names>P</given-names></name></person-group><article-title>Cutting edge: RANTES regulates Fas ligand expressionand killing by HIV-specific CD8 cytotoxic T cells</article-title><source>J Immunol</source><year>1999</year><volume>163</volume><fpage>1105</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10415001</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>OO</given-names></name><name><surname>Garcia-Zepeda</surname><given-names>EA</given-names></name><name><surname>Ge</surname><given-names>Y</given-names></name><name><surname>Kalams</surname><given-names>SA</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name><etal/></person-group><article-title>Beta-chemokines are released from HIV-1-specificcytolytic T-cell granules complexed to proteoglycans</article-title><source>Nature</source><year>1998</year><volume>391</volume><fpage>908</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">9495345</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migueles</surname><given-names>SA</given-names></name><name><surname>Laborico</surname><given-names>AC</given-names></name><name><surname>Shupert</surname><given-names>WL</given-names></name><name><surname>Sabbaghian</surname><given-names>MS</given-names></name><name><surname>Rabin</surname><given-names>R</given-names></name><name><surname>Hallahan</surname><given-names>CW</given-names></name><etal/></person-group><article-title>HIV-specific CD8+ T cell proliferation is coupledto perforin expression and is maintained in nonprogressors</article-title><source>Nat Immunol</source><year>2002</year><volume>3</volume><fpage>1061</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12368910</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostrikis</surname><given-names>LG</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Ngai</surname><given-names>H</given-names></name><name><surname>Moore</surname><given-names>JP</given-names></name><name><surname>Ho</surname><given-names>DD</given-names></name></person-group><article-title>Quantitativeanalysis of serum neutralization of human immunodeficiency virustype 1 from subtypes A, B, C, D, E, F, and I:lack of direct correlationbetween neutralization serotypes and genetic subtypes andevidence for prevalent serum-dependent infectivity enhancement</article-title><source>J Virol</source><year>1996</year><volume>70</volume><fpage>445</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">8523557</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hengel</surname><given-names>RL</given-names></name><name><surname>Kennedy</surname><given-names>MS</given-names></name><name><surname>Steketee</surname><given-names>RW</given-names></name><name><surname>Thea</surname><given-names>DM</given-names></name><name><surname>Abrams</surname><given-names>EJ</given-names></name><name><surname>Lambert</surname><given-names>G</given-names></name><etal/></person-group><article-title>Neutralizing antibody and perinatal transmissionof human immunodeficiency virus type 1</article-title><source>AIDS Res Hum Retroviruses</source><year>1998</year><volume>14</volume><fpage>475</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">9566549</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>DD</given-names></name></person-group><article-title>Time to hit HIV, early and hard</article-title><source>N Engl J Med</source><year>1995</year><volume>333</volume><fpage>450</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">7616996</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belfort</surname><given-names>R</given-names></name></person-group><article-title>The ophthalmologist and the Global impact of the AIDSepidemic: LV Edward Jackson Memorial Lecture</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>1</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10653405</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jabs</surname><given-names>DA</given-names></name><name><surname>Bartlett</surname><given-names>JG</given-names></name></person-group><article-title>AIDS and Ophthalmology: A period of transition</article-title><source>Am J Ophthalmol</source><year>1997</year><volume>124</volume><fpage>227</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">9262548</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MR</given-names></name><name><surname>Reed</surname><given-names>G</given-names></name><name><surname>Csaky</surname><given-names>KG</given-names></name><name><surname>Polis</surname><given-names>MA</given-names></name><name><surname>Whitcup</surname><given-names>SM</given-names></name></person-group><article-title>Immune-recovery uveitis in patients with cytomegalovirus retinitis takinghighly active antiretroviral therapy</article-title><source>Am J Ophthalmol</source><year>2000</year><volume>130</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">11004259</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tural</surname><given-names>C</given-names></name><name><surname>Romeu</surname><given-names>J</given-names></name><name><surname>Sirera</surname><given-names>G</given-names></name><name><surname>Andreu</surname><given-names>D</given-names></name><name><surname>Conejero</surname><given-names>M</given-names></name><name><surname>Ruiz</surname><given-names>S</given-names></name><etal/></person-group><article-title>Long lasting remission of cytomegalovirus retinitis withoutmaintenance therapy in human immunodeficiency virus-infectedpatients</article-title><source>J Infect Dis</source><year>1998</year><volume>177</volume><fpage>1080</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">9534987</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macdonald</surname><given-names>JC</given-names></name><name><surname>Torriani</surname><given-names>FJ</given-names></name><name><surname>Morse</surname><given-names>LS</given-names></name><name><surname>Karavellas</surname><given-names>MP</given-names></name><name><surname>Reed</surname><given-names>JB</given-names></name><name><surname>Freeman</surname><given-names>WR</given-names></name></person-group><article-title>Lack of reactivation of cytomegalovirus retinitisafter stopping CMV maintenance therapy in AIDS patients withsustained elevations in CD4 T cells in response to highly activeantiretroviral therapy</article-title><source>J Infect Dis</source><year>1998</year><volume>177</volume><fpage>1182</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9593001</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karavellas</surname><given-names>MP</given-names></name><name><surname>Azen</surname><given-names>SP</given-names></name><name><surname>MacDonald</surname><given-names>JC</given-names></name><name><surname>Shufelt</surname><given-names>CL</given-names></name><name><surname>Lowder</surname><given-names>CY</given-names></name><name><surname>Plummer</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Immune recovery vitritis and uveitis in AIDS:Clinical predictors, sequelae and treatment outcomes</article-title><source>Retina</source><year>2001</year><volume>21</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11217922</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zegans</surname><given-names>ME</given-names></name><name><surname>Walton</surname><given-names>RC</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name><name><surname>O&#x02032;Donnell</surname><given-names>JJ</given-names></name><name><surname>Jacobson</surname><given-names>MA</given-names></name><name><surname>Margolis</surname><given-names>TP</given-names></name></person-group><article-title>Transient vitreous inflammatory reactions associatedwith combination antiretroviral therapy in patients with AIDS andcytomegalovirus retinitis</article-title><source>Am J Ophthalmol</source><year>1998</year><volume>125</volume><fpage>292</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">9512145</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrier</surname><given-names>RD</given-names></name><name><surname>Song</surname><given-names>MK</given-names></name><name><surname>Smith</surname><given-names>IL</given-names></name><name><surname>Karavellas</surname><given-names>MP</given-names></name><name><surname>Bartsch</surname><given-names>DU</given-names></name><name><surname>Torriani</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Intraocular viral and immune pathogenesis ofimmune recovery uveitis in patients with healed cytomegalovirusretinitis</article-title><source>Retina</source><year>2006</year><volume>26</volume><fpage>165</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16467672</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modorati</surname><given-names>G</given-names></name><name><surname>Miserocchi</surname><given-names>E</given-names></name><name><surname>Brancato</surname><given-names>R</given-names></name></person-group><article-title>Immune recovery uveitisand human leukocyte antigen typing: A report on four patients</article-title><source>Eur J Ophthalmol</source><year>2005</year><volume>15</volume><fpage>607</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16167291</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>J</given-names></name><name><surname>Fogla</surname><given-names>R</given-names></name><name><surname>Gopal</surname><given-names>L</given-names></name><name><surname>Narayana</surname><given-names>KM</given-names></name><name><surname>Banker</surname><given-names>AS</given-names></name><name><surname>Kumarasamy</surname><given-names>N</given-names></name><etal/></person-group><article-title>Current approaches to diagnosis andmanagement of ocular lesions in human immunodeficiency viruspositive patients</article-title><source>Indian J Ophthalmol</source><year>2002</year><volume>50</volume><fpage>83</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">12194584</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>Schematic diagram of a human immunodeficiency virus</p></caption><alt-text>Figure 1</alt-text><graphic xlink:href="IndianJOphthalmol-56-357-g001"/></fig></floats-group></article>